Purpose: Homologous DNA repair-deficient (HRD) ovarian cancers (OCs), including those with BRCA1/2 mutations, have higher levels of genetic instability, potentially resulting in higher immunogenicity, and have been suggested to respond better to immune checkpoint inhibitors (ICIs) than homologous DNA repair-proficient OCs. However, clinical evidence is lacking. The study aimed to evaluate the associations between BRCA1/2 mutations, HRD, and other genomic parameters and response to ICIs and survival in OC., Methods: This is a single-institution retrospective analysis of women with recurrent OC treated with ICIs. BRCA1/2 mutation status and clinicopathologic variables were abstracted from the medical records. Targeted and whole-exome sequencing data available for a subset of patients were used to assess tumor mutational burden (TMB), HRD, and fraction of genome altered (FGA). ICI response was defined as lack of disease progression for ≥ 24 weeks. Associations of BRCA1/2 status and genomic alterations with progression-free survival (PFS) and overall survival (OS) were determined using Cox proportional hazards models., Results: Of the 143 women treated with ICIs, 134 had known BRCA1/2 mutation status. Deleterious germline or somatic BRCA1/2 mutations were present in 31 women (24%). There was no association between presence of BRCA1/2 mutations and response ( P = .796) or survival. Genomic analysis in 73 women found no association between TMB ( P = .344) or HRD ( P = .222) and response, PFS, or OS. There were also no significant differences in somatic genetic alterations between responders and nonresponders. High FGA was associated with an improvement in PFS ( P = .014) and OS ( P = .01)., Conclusion: TMB, BRCA1/2 mutations, and HRD are not associated with response or survival, cautioning against their use as selection criteria for ICI in recurrent OC. FGA should be investigated further as a biomarker of response to immunotherapy in OC., Competing Interests: The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Alexia IasonosConsulting or Advisory Role: Mylan, Brightpath, IntelligenciaMargaret CallahanEmployment: Bristol Myers Squibb (I), Celgene (I), Kleo Pharmaceuticals (I) Consulting or Advisory Role: AstraZeneca, Moderna Therapeutics, Merck, Immunocore Research Funding: Bristol Myers Squibb (Inst) Other Relationship: Clinical Care Options, Potomac Center for Medical EducationIgnacio Vazquez-GarciaStock and Other Ownership Interests: CRISPR Therapeutics, Editas MedicineAhmet ZehirHonoraria: IlluminaRobert A. BurgerEmployment: Genentech Stock and Other Ownership Interests: Genentech Consulting or Advisory Role: AstraZeneca, Tesaro, Merck, Genentech, Morphotek, Myriad Genetics Research Funding: Incyte (Inst), Astra Zeneca (Inst), and Genzyme (Inst) Travel, Accommodations, Expenses: Tesaro, GenentechDaniel J. Powell JrStock and Other Ownership Interests: Atara Biotherapeutics, InsTIL Bio Consulting or Advisory Role: Neon Therapeutics, Iovance Biotherapeutics, Tmunity Therapeutics, InsTIL Bio, Bellicum Pharmaceuticals Research Funding: Eli Lilly, Tmunity Therapeutics, Incyte, Monojul, AstraZeneca/MedImmune Patents, Royalties, Other Intellectual Property: I hold patents in the field of chimeric antigen receptor (CAR) T-cell therapy in oncology and have received royalties related to their licensing to Novartis; I hold patents in the field of CAR T cell therapy in Oncology and have received royalties related to their licensing to Tmunity Travel, Accommodations, Expenses: Iovance BiotherapeuticsClaire FriedmanConsulting or Advisory Role: AstraZeneca/MedImmune Research Funding: Bristol Myers Squibb (Inst), Arcus Biosciences (Inst), Genentech (Inst), Merck (Inst) Other Relationship: Guidepoint Global Uncompensated Relationships: Genentech, Merck Open Payments Link: https://openpaymentsdata.cms.gov/physician/477023/summaryKaren CadooHonoraria: OncLive Consulting or Advisory Role: GSK Tesaro Research Funding: AstraZeneca (Inst), Syndax (Inst) Travel, Accommodations, Expenses: AstraZenecaRachel GrishamConsulting or Advisory Role: Mateon Therapeutics, Clovis Oncology, Regeneron Research Funding: Context Therapeutics (Inst) Travel, Accommodations, Expenses: EMD Serono Other Relationship: Prime Oncology, MCM Education, OncLiveJason A. KonnerConsulting or Advisory Role: Immunogen, AstraZeneca, Tesaro, AbbVie Research Funding: Genentech Travel, Accommodations, Expenses: AstraZenecaRoisin E. O'CearbhaillConsulting or Advisory Role: Tesaro, GlaxoSmithKline Research Funding: Juno Therapeutics (Inst), Sellas Life Sciences (Inst), Ludwig Institute for Cancer Research (Inst), Stem CentRx (Inst), TapImmune (Inst), TCR2 Therapeutics (Inst), Regeneron (Inst), Genmab (Inst)Carol AghajanianConsulting or Advisory Role: Tesaro, Mersana, Eisai, Roche Research Funding: Genentech (Inst), AbbVie (Inst), Clovis Oncology (Inst), AstraZeneca (Inst), Clovis Oncology (Inst), AstraZeneca (Inst)Jorge S. Reis-FilhoConsulting or Advisory Role: Genentech, Invicro, Ventana Medical Systems, Volition RX, Paige AI, Goldman Sachs, Novartis, Repare TherapeuticsBritta WeigeltConsulting or Advisory Role: Genentech (I), Invicro (I), Ventana Medical Systems (I), Volition RX (I), Page AI (I), Goldman Sachs (I), Repare Therapeutics (I)Dmitriy ZamarinConsulting or Advisory Role: Merck, Synlogic, Western Oncolytics, Tesaro, Agenus, Trieza Therapeutics, ACM Biolabs Research Funding: Genentech (Inst) Patents, Royalties, Other Intellectual Property: I hold a patent regarding the use of recombinant Newcastle disease virus (NDV) for cancer therapy (Inst) No other potential conflicts of interest were reported., (© 2020 by American Society of Clinical Oncology.)